Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes.

Journal: Dermatology and therapy
Published Date: May 11, 2025

Abstract

INTRODUCTION: This randomized, prospective study (MATCH) was designed to assess the clinical utility of a machine learning-based tool (Mind.Px) that predicts patient response to the biologic drug classes used in the management of psoriasis.

Authors

  • Bruce E Strober
    Yale University School of Medicine, New Haven, CT, USA. brucestrober30@me.com.
  • Michael Bukhalo
    Arlington Dermatology, Rolling Meadows, IL, USA.
  • April W Armstrong
    Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • David Pariser
    Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA.
  • Leon Kircik
    Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Brian Johnson
    Virginia Dermatology and Skin Cancer Center, Norfolk, VA, USA.
  • Paul Montgomery
    ICube Research Institute, University of Strasbourg - CNRS - INSA de Strasbourg, 300 Bd. Sébastien Brant, 67412 Illkirch, France.
  • Tobin J Dickerson
    Mindera Health, Vista, CA, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals